tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Bactiguard Reports Positive EBITDA Momentum Amid Revenue Decline in Q2 2025

Story Highlights
Bactiguard Reports Positive EBITDA Momentum Amid Revenue Decline in Q2 2025

Elevate Your Investing Strategy:

An update from Bactiguard Holding AB ( ($SE:BACTI.B) ) is now available.

Bactiguard Holding AB reported a positive EBITDA momentum in the second quarter of 2025, despite a decrease in total revenue and net sales due to currency effects and delays in market registration. The company initiated early feasibility work in the cardiology therapeutic area, which presents significant potential, and continues to focus on strengthening partnerships and driving growth in its strategic areas.

The most recent analyst rating on ($SE:BACTI.B) stock is a Sell with a SEK47.00 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.

More about Bactiguard Holding AB

Bactiguard Holding AB operates in the medical technology industry, focusing on infection prevention solutions. The company specializes in developing and providing coatings for medical devices to prevent infections, with a significant market focus on partnerships with companies like BD and Zimmer Biomet.

Average Trading Volume: 5,197

Current Market Cap: SEK995.2M

See more data about BACTI.B stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1